Literature DB >> 14963130

Investigation of the susceptibility of human cell lines to bovine herpesvirus 4 infection: demonstration that human cells can support a nonpermissive persistent infection which protects them against tumor necrosis factor alpha-induced apoptosis.

L Gillet1, F Minner, B Detry, F Farnir, L Willems, M Lambot, E Thiry, P-P Pastoret, F Schynts, A Vanderplasschen.   

Abstract

Bovine herpesvirus 4 (BoHV-4) is a gammaherpesvirus that has a worldwide distribution in the population of cattle. Many factors make human contamination by BoHV-4 likely to occur. In this study, we performed in vitro experiments to assess the risk and the consequences of human infection by BoHV-4. First, by using a recombinant BoHV-4 strain expressing enhanced green fluorescent protein under the control of the human cytomegalovirus immediate-early gene promoter, we tested 21 human cell lines for their sensitivity and their permissiveness to BoHV-4 infection. These experiments revealed that human cell lines from lymphoid and myeloid origins were resistant to infection, whereas epithelial cells, carcinoma cells, or adenocarcinoma cells isolated from various organs were sensitive but poorly permissive to BoHV-4 infection. Second, by using the HeLa cell line as a model of human cells sensitive but not permissive to BoHV-4 infection, we investigated the resistance of infected cells to apoptosis and the persistence of the infection through cellular divisions. The results obtained can be summarized as follows. (i) BoHV-4 nonpermissive infection of HeLa cells protects them against tumor necrosis factor alpha-induced apoptosis. (ii) BoHV-4 infection of HeLa cells persists in cell culture; however, the percentage of infected cells decreases with time due to erratic transmission of the viral genome through cell division. (iii) BoHV-4 infection has no effect on the rate of HeLa cell division. Altogether, these data suggest that BoHV-4 could infect humans. This study also stresses the importance of considering the insidious effects of nonpermissive infection when the biosafety of animal gammaherpesviruses for humans is being considered.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14963130      PMCID: PMC369250          DOI: 10.1128/jvi.78.5.2336-2347.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells.

Authors:  Jianhong Hu; Alexander C Garber; Rolf Renne
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus permits replication of terminal repeat-containing plasmids.

Authors:  Adam Grundhoff; Don Ganem
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

3.  Construction of plasmids that express E. coli beta-galactosidase in mammalian cells.

Authors:  G R MacGregor; C T Caskey
Journal:  Nucleic Acids Res       Date:  1989-03-25       Impact factor: 16.971

4.  Analysis of gene expression in a human cell line stably transduced with herpesvirus saimiri.

Authors:  K T Hall; M S Giles; D J Goodwin; M A Calderwood; I M Carr; A J Stevenson; A F Markham; A Whitehouse
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Morphogenesis of a cytomegalovirus from an American bison affected with malignant catarrhal fever.

Authors:  W J Todd; J Storz
Journal:  J Gen Virol       Date:  1983-05       Impact factor: 3.891

6.  Establishment of a cell line persistently infected with bovine herpesvirus-4 by use of a recombinant virus.

Authors:  G Donofrio; S Cavirani; V L van Santen
Journal:  J Gen Virol       Date:  2000-07       Impact factor: 3.891

Review 7.  Infectious disease issues in xenotransplantation.

Authors:  R S Boneva; T M Folks; L E Chapman
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

8.  Induction of thymidine kinase activity by viruses with group B DNA genomes: bovine cytomegalovirus (bovine herpesvirus 4).

Authors:  S Kit; M Kit; H Ichimura; R Crandell; S McConnell
Journal:  Virus Res       Date:  1986-02       Impact factor: 3.303

9.  A herpesvirus saimiri-based gene therapy vector with potential for use in cancer immunotherapy.

Authors:  A J Stevenson; E Frolova-Jones; K T Hall; S E Kinsey; A F Markham; A Whitehouse; D M Meredith
Journal:  Cancer Gene Ther       Date:  2000-07       Impact factor: 5.987

10.  Epidemiology of herpesvirus papio infection in a large captive baboon colony: similarities to Epstein-Barr virus infection in humans.

Authors:  H B Jenson; Y Ench; S J Gao; K Rice; D Carey; R C Kennedy; J R Arrand; M Mackett
Journal:  J Infect Dis       Date:  2000-04-13       Impact factor: 5.226

View more
  10 in total

1.  Herpes simplex virus type 1 thymidine kinase-armed bovine herpesvirus type 4-based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma models.

Authors:  Marco Redaelli; Valentina Franceschi; Antonio Capocefalo; Domenico D'Avella; Luca Denaro; Sandro Cavirani; Carla Mucignat-Caretta; Gaetano Donofrio
Journal:  Neuro Oncol       Date:  2012-01-06       Impact factor: 12.300

2.  Bovine herpesvirus 4 based vector as a potential oncolytic-virus for treatment of glioma.

Authors:  Marco Redaelli; Carla Mucignat-Caretta; Andrea Cavaggioni; Antonio Caretta; Domenico D'Avella; Luca Denaro; Sandro Cavirani; Gaetano Donofrio
Journal:  Virol J       Date:  2010-11-03       Impact factor: 4.099

3.  Comparative study on the in vitro replication and genomic variability of Argentinean field isolates of bovine herpesvirus type 4 (BoHV-4).

Authors:  A E Verna; S E Pérez; J M Manrique; M R Leunda; A C Odeón; L R Jones
Journal:  Virus Genes       Date:  2016-03-19       Impact factor: 2.332

4.  The bovine herpesvirus 4 Bo10 gene encodes a nonessential viral envelope protein that regulates viral tropism through both positive and negative effects.

Authors:  Bénédicte Machiels; Céline Lété; Katalin de Fays; Jan Mast; Benjamin Dewals; Philip G Stevenson; Alain Vanderplasschen; Laurent Gillet
Journal:  J Virol       Date:  2010-11-10       Impact factor: 5.103

Review 5.  Evaluation of the human host range of bovine and porcine viruses that may contaminate bovine serum and porcine trypsin used in the manufacture of biological products.

Authors:  Carol Marcus-Sekura; James C Richardson; Rebecca K Harston; Nandini Sane; Rebecca L Sheets
Journal:  Biologicals       Date:  2011-10-13       Impact factor: 1.856

6.  Molecular Characterization of the First Bovine Herpesvirus 4 (BoHV-4) Strains Isolated from In Vitro Bovine Embryos production in Argentina.

Authors:  Erika González Altamiranda; Julieta M Manrique; Sandra E Pérez; Glenda L Ríos; Anselmo C Odeón; María R Leunda; Leandro R Jones; Andrea Verna
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

7.  In vivo image analysis of BoHV-4-based vector in mice.

Authors:  Valentina Franceschi; Fabio Franco Stellari; Carlo Mangia; Sarah Jacca; Sophia Lavrentiadou; Sandro Cavirani; Mathias Heikenwalder; Gaetano Donofrio
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

8.  Bovine herpesvirus 4 is tropic for bovine endometrial cells and modulates endocrine function.

Authors:  Gaetano Donofrio; Shan Herath; Chiara Sartori; Sandro Cavirani; Cesidio Filippo Flammini; Iain Martin Sheldon
Journal:  Reproduction       Date:  2007-07       Impact factor: 3.906

9.  Transduction of the rat brain by Bovine Herpesvirus 4.

Authors:  Marco Redaelli; Andrea Cavaggioni; Carla Mucignat-Caretta; Sandro Cavirani; Antonio Caretta; Gaetano Donofrio
Journal:  Genet Vaccines Ther       Date:  2008-02-12

10.  Malignant catarrhal fever induced by alcelaphine herpesvirus 1 is associated with proliferation of CD8+ T cells supporting a latent infection.

Authors:  Benjamin Dewals; Christel Boudry; Frédéric Farnir; Pierre-Vincent Drion; Alain Vanderplasschen
Journal:  PLoS One       Date:  2008-02-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.